WO2002043774A3 - Compositions and therapeutical use of polynucleotides encoding tcrs - Google Patents

Compositions and therapeutical use of polynucleotides encoding tcrs Download PDF

Info

Publication number
WO2002043774A3
WO2002043774A3 PCT/US2001/050673 US0150673W WO0243774A3 WO 2002043774 A3 WO2002043774 A3 WO 2002043774A3 US 0150673 W US0150673 W US 0150673W WO 0243774 A3 WO0243774 A3 WO 0243774A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides encoding
compositions
therapeutical use
encoding tcrs
polynucleotides
Prior art date
Application number
PCT/US2001/050673
Other languages
French (fr)
Other versions
WO2002043774A2 (en
Inventor
Juan Harrison
Original Assignee
Powderject Vaccines Inc
Juan Harrison
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc, Juan Harrison filed Critical Powderject Vaccines Inc
Priority to AU2002241726A priority Critical patent/AU2002241726A1/en
Priority to EP01988417A priority patent/EP1392365A2/en
Priority to US10/415,745 priority patent/US20040048822A1/en
Priority to JP2002545744A priority patent/JP2004535358A/en
Publication of WO2002043774A2 publication Critical patent/WO2002043774A2/en
Publication of WO2002043774A3 publication Critical patent/WO2002043774A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Abstract

Polynucleotides encoding T-cell receptors and compositions and methods of use these polynucleotides are provided. The invention includes polynucleotides encoding at least one T-cell receptor or fragments thereof, core carriers coated with these polynucleotides and methods of treating T-cell mediated diseases in a subject.
PCT/US2001/050673 2000-11-02 2001-11-01 Compositions and therapeutical use of polynucleotides encoding tcrs WO2002043774A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2002241726A AU2002241726A1 (en) 2000-11-02 2001-11-01 Compositions and therapeutical use of polynucleotides encoding tcrs
EP01988417A EP1392365A2 (en) 2000-11-02 2001-11-01 Compositions and therapeutical use of polynucleotides encoding tcrs
US10/415,745 US20040048822A1 (en) 2001-11-01 2001-11-01 Nucleic acid immunization
JP2002545744A JP2004535358A (en) 2000-11-02 2001-11-01 Nucleic acid immunity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24548100P 2000-11-02 2000-11-02
US60/245,481 2000-11-02

Publications (2)

Publication Number Publication Date
WO2002043774A2 WO2002043774A2 (en) 2002-06-06
WO2002043774A3 true WO2002043774A3 (en) 2003-12-04

Family

ID=22926841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050673 WO2002043774A2 (en) 2000-11-02 2001-11-01 Compositions and therapeutical use of polynucleotides encoding tcrs

Country Status (4)

Country Link
EP (1) EP1392365A2 (en)
JP (1) JP2004535358A (en)
AU (1) AU2002241726A1 (en)
WO (1) WO2002043774A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008043157A1 (en) 2006-10-12 2008-04-17 The University Of Queensland Compositions and methods for modulating immune responses
DK2635596T3 (en) 2010-11-01 2019-11-25 Univ Sydney Technology IMMUN MODULATORS AND USES THEREOF

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5865796A (en) * 1994-01-21 1999-02-02 Powderject Vaccines, Inc Gas driven gene delivery instrument
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6090387A (en) * 1989-03-21 2000-07-18 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses
WO2000063385A2 (en) * 1999-04-21 2000-10-26 Powderject Vaccines, Inc. Nucleic acid immunization

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090387A (en) * 1989-03-21 2000-07-18 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses
US5865796A (en) * 1994-01-21 1999-02-02 Powderject Vaccines, Inc Gas driven gene delivery instrument
US5939400A (en) * 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
WO2000063385A2 (en) * 1999-04-21 2000-10-26 Powderject Vaccines, Inc. Nucleic acid immunization

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEGANO P ET AL: "Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect? system", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 16, no. 4, 1 February 1998 (1998-02-01), pages 394 - 398, XP004099300, ISSN: 0264-410X *
WAISMAN A ET AL: "SUPPRESSIVE VACCINATION WITH DNA ENCODING A VARIABLE REGION GENE OF THE T-CELL RECEPTOR PREVENTS AUTOIMMUNE ENCEPHALOMYELITIS AND ACTIVATES TH2 IMMUNITY", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 2, no. 8, 1 August 1996 (1996-08-01), pages 899 - 905, XP002073619, ISSN: 1078-8956 *

Also Published As

Publication number Publication date
AU2002241726A1 (en) 2002-06-11
WO2002043774A2 (en) 2002-06-06
JP2004535358A (en) 2004-11-25
EP1392365A2 (en) 2004-03-03

Similar Documents

Publication Publication Date Title
TWI371450B (en) Novel substituted dihydro 3-halo-1h-pyrazole-5-carboxylates,their preparation and use
WO2003018516A3 (en) Glucagon-like peptide-1 analogs
HUP0102833A3 (en) Cyclosporins, process for preparation thereof and their use
PL366829A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
GB0507735D0 (en) Protein-silane/siloxane copolymers, their preparation and their use
MXPA03000753A (en) Benzimidazole derivatives, preparation and therapeutic use thereof.
HK1036976A1 (en) Benzimidazoles, production thereof and use thereofas medicaments.
WO1999029729A3 (en) Antagonists of neuropilin receptor function and use thereof
AU2002359126A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
MXPA03000574A (en) Glass-ceramics, process for their preparation and use.
ZA97910B (en) Mixtures which can be isolated from Eugenia Jambolana Lamarck seeds, their preparation and their use as medicaments.
AU2001235595A1 (en) 4-heteroaryl-1,4-diazabicyclo(3.2.2)nonane, preparation and therapeutic use thereof
AU2002359123A8 (en) Benzodiazepine derivatives, preparation thereof and use thereof
AU6246199A (en) Human interleukin-b50, therapeutic uses
AU2001264042A1 (en) 1,4-diazabicyclo(3.2.2)nonane-phenylisoxazole derivatives, preparation and therapeutic use thereof
HK1040980A1 (en) Biphenylsulfonylcyanamides,process for their preparation, and their use as medicament
EP0743314A3 (en) Carbosilane dendrimers, their preparation and their use
WO2002043774A3 (en) Compositions and therapeutical use of polynucleotides encoding tcrs
HUP0004330A3 (en) Synergetic fungicidal mixture based on pyridin carboxamides and benzimidazoles or the precursors thereof, and its use
AU1138699A (en) Dna demethylase, therapeutic and diagnostic uses thereof
MXPA01011720A (en) Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods.
IT1304598B1 (en) INHALATION EQUIPMENT AND RELATED PROCEDURE.
AU2001248971A1 (en) Use of npy y1 receptor agonists in the treatment of pain conditions
WO2002057313A8 (en) Receptor-binding compounds and methods for identifying them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002545744

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001988417

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10415745

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001988417

Country of ref document: EP